India · Delayed Price · Currency is INR Concord Drugs Statistics
Total Valuation
Concord Drugs has a market cap or net worth of INR 1.03 billion. The enterprise value is 900.05 million.
| Market Cap | 1.03B |
| Enterprise Value | 900.05M |
Important Dates
The last earnings date was Wednesday, May 27, 2026.
| Earnings Date | May 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Concord Drugs has 13.18 million shares outstanding. The number of shares has increased by 11.05% in one year.
| Current Share Class | 13.18M |
| Shares Outstanding | 13.18M |
| Shares Change (YoY) | +11.05% |
| Shares Change (QoQ) | -17.13% |
| Owned by Insiders (%) | 66.79% |
| Owned by Institutions (%) | n/a |
| Float | 4.38M |
Valuation Ratios
The trailing PE ratio is 82.03.
| PE Ratio | 82.03 |
| Forward PE | n/a |
| PS Ratio | 1.30 |
| PB Ratio | 2.12 |
| P/TBV Ratio | 2.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 85.31 |
| EV / Sales | 1.14 |
| EV / EBITDA | 19.92 |
| EV / EBIT | 28.55 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.53, with a Debt / Equity ratio of 0.30.
| Current Ratio | 2.53 |
| Quick Ratio | 1.19 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | 3.21 |
| Debt / FCF | -1.83 |
| Interest Coverage | 1.84 |
Financial Efficiency
Return on equity (ROE) is 2.55% and return on invested capital (ROIC) is 3.91%.
| Return on Equity (ROE) | 2.55% |
| Return on Assets (ROA) | 2.81% |
| Return on Invested Capital (ROIC) | 3.91% |
| Return on Capital Employed (ROCE) | 5.86% |
| Weighted Average Cost of Capital (WACC) | 7.32% |
| Revenue Per Employee | 3.15M |
| Profits Per Employee | 42,200 |
| Employee Count | 250 |
| Asset Turnover | 1.12 |
| Inventory Turnover | 2.66 |
Taxes
In the past 12 months, Concord Drugs has paid 4.18 million in taxes.
| Income Tax | 4.18M |
| Effective Tax Rate | 28.39% |
Stock Price Statistics
The stock price has increased by +160.20% in the last 52 weeks. The beta is 0.53, so Concord Drugs's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +160.20% |
| 50-Day Moving Average | 80.85 |
| 200-Day Moving Average | 76.39 |
| Relative Strength Index (RSI) | 45.25 |
| Average Volume (20 Days) | 6,338 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Drugs had revenue of INR 787.37 million and earned 10.55 million in profits. Earnings per share was 0.95.
| Revenue | 787.37M |
| Gross Profit | 110.91M |
| Operating Income | 31.53M |
| Pretax Income | 14.73M |
| Net Income | 10.55M |
| EBITDA | 45.19M |
| EBIT | 31.53M |
| Earnings Per Share (EPS) | 0.95 |
Balance Sheet
The company has 7.51 million in cash and 145.08 million in debt, with a net cash position of -137.58 million or -10.44 per share.
| Cash & Cash Equivalents | 7.51M |
| Total Debt | 145.08M |
| Net Cash | -137.58M |
| Net Cash Per Share | -10.44 |
| Equity (Book Value) | 485.14M |
| Book Value Per Share | 43.18 |
| Working Capital | 322.44M |
Cash Flow
In the last 12 months, operating cash flow was -67.66 million and capital expenditures -11.67 million, giving a free cash flow of -79.33 million.
| Operating Cash Flow | -67.66M |
| Capital Expenditures | -11.67M |
| Depreciation & Amortization | 13.67M |
| Net Borrowing | -35.93M |
| Free Cash Flow | -79.33M |
| FCF Per Share | -6.02 |
Margins
Gross margin is 14.09%, with operating and profit margins of 4.00% and 1.34%.
| Gross Margin | 14.09% |
| Operating Margin | 4.00% |
| Pretax Margin | 1.87% |
| Profit Margin | 1.34% |
| EBITDA Margin | 5.74% |
| EBIT Margin | 4.00% |
| FCF Margin | n/a |
Dividends & Yields
Concord Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.05% |
| Shareholder Yield | -11.05% |
| Earnings Yield | 1.03% |
| FCF Yield | -7.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |